Highlights of the 29th Congress of the European Committee for Treatment and Research in MS (ECTRIMS), Copenhagen, DK, October 2-5, 2013 – The Canadian MS HSCT Study is a phase II trial in which patients with aggressive MS receive ablative chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). The procedure appears to stabilize disease progression in a majority of patients, according to the results now presented (Freedman et al. ECTRIMS 2013; abstract P 543).